Indaptus Therapeutics (NASDAQ:INDP) Issues Earnings Results, Beats Expectations By $1.26 EPS

Indaptus Therapeutics (NASDAQ:INDP) issued its earnings results on Tuesday. The company reported ($3.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($4.36) by $1.26, FiscalAI reports.

Indaptus Therapeutics Stock Up 9.1%

Shares of NASDAQ INDP traded up $0.16 during trading hours on Tuesday, hitting $1.91. 15,801 shares of the stock were exchanged, compared to its average volume of 68,951. Indaptus Therapeutics has a 12 month low of $1.52 and a 12 month high of $47.60. The firm has a fifty day moving average price of $2.22 and a 200-day moving average price of $2.72. The company has a market cap of $4.28 million, a PE ratio of -0.06 and a beta of 0.97.

Institutional Investors Weigh In On Indaptus Therapeutics

A hedge fund recently bought a new stake in Indaptus Therapeutics stock. Virtu Financial LLC purchased a new position in shares of Indaptus Therapeutics, Inc. (NASDAQ:INDP) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 18,997 shares of the company’s stock, valued at approximately $55,000. Virtu Financial LLC owned about 1.72% of Indaptus Therapeutics at the end of the most recent quarter. 7.06% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on INDP. Wall Street Zen cut shares of Indaptus Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, December 6th. Weiss Ratings reissued a “sell (e+)” rating on shares of Indaptus Therapeutics in a research note on Thursday, January 22nd. One analyst has rated the stock with a Sell rating, According to MarketBeat, the stock currently has a consensus rating of “Sell”.

About Indaptus Therapeutics

Indaptus Therapeutics, Inc, is a clinical-stage biotechnology company focused on developing novel cell- and exosome-based immunotherapies for oncology and infectious diseases. Utilizing its proprietary Natural Killer (NK) Cell Platform, Indaptus engineers allogeneic NK cells with enhanced cytotoxicity and targeted tumor recognition. The company’s Exo-NK Therapeutics program further leverages NK cell–derived exosomes to deliver bioactive molecules and amplify immune responses against disease.

Indaptus’ pipeline includes multiple preclinical candidates that integrate chimeric antigen receptor (CAR) technology with NK cells and exosomes to address hematologic malignancies and solid tumors.